BioCentury | Feb 5, 2021
Emerging Company Profile

Deals with Allogene, ADC reflect Overland’s ambition to tap parent Hillhouse’s network to bring innovation to China

...Euronext:SAN; NASDAQ:SNY). Mu is a veteran of Simcere Pharmaceutical Group Ltd....
...president of R&D and later president of Simcere’s...
BioCentury | Dec 31, 2020
Regulation

119 drugs added to China’s reimbursement list, which includes more domestic PD-1s

...Commission.Over 85% of NHSA’s disease categories were covered by added drugs, including Sanbexin edaravone/dexborneol from Simcere Pharmaceutical Group Ltd....
BioCentury | Dec 22, 2020
Regulation

Dec. 21-23 Regulatory Quick Takes: positive CHMP opinion for Pfizer-BioNTech COVID-19 vaccine; plus Urovant’s approval, a Feb. 9 adcomm for Keytruda in TNBC, NMPA reviewing a subcutaneous PD-L1, and more

...from urge urinary incontinence, urgency and urinary frequency.NMPA reviewing subcutaneous PD-L1 inhibitorAlphamab Oncology Ltd. and Simcere Pharmaceutical Group Ltd....
...deficient (dMMR) solid tumors. If approved, envafolimab could become the first subcutaneous anti-PD-1/PD-L1 antibody globally. Simcere...
BioCentury | Dec 15, 2020
Deals

Hillhouse’s Overland builds momentum with second marquee China deal with Allogene

...as a drug developer includes tenures at Simcere Pharmaceutical Group Ltd....
...president of R&D and later president of Simcere’s...
BioCentury | Dec 15, 2020
Deals

ADC Therapeutics caps year of milestones by building bridge to China via Hillhouse-backed Overland’s debut deal

...CMO Hua Mu, is a veteran of Simcere Pharmaceutical Group Ltd....
...president of R&D and later president of Simcere’s...
BioCentury | Oct 28, 2020
Finance

Oct. 27 Financial Quick Takes: Apellis-Sobi deal for C3 inhibitor; plus Primmune, Prokarium, Novartis-RegenxBio, Turning Point, Psyomics, Journey Colab

...reimbursements. It’s also eligible for $915 million in milestones.Simcere slips in Hong Kong debutShares of Simcere Pharmaceutical Group Ltd....
...The deal came at a valuation of about $4.6 billion. Once primarily a generics company, Simcere...
BioCentury | Oct 15, 2020
Product Development

Oct. 14 Quick Takes: FDA approves first Ebola therapy; plus Vertex tumbles after hours on AAT discontinuation

...Ventures and Octopus Ventures. Existing investors Amadeus Capital Partners, Delin Ventures and Kindred Capital also participated.Simcere...
...the midpoint, the company would raise HK$3.4 billion (US$433.7 million) and be valued HK$33.6 billion. Simcere...
...SGI-110, s110) Makena (gestiva, hydroxyprogesterone caproate injection, 17P) Regeneron Pharmaceuticals Inc. Vertex Pharmaceuticals Inc. Otsuka Pharmaceutical Factory Inc. Ori Biotech Ltd. Simcere Pharmaceutical Group Ltd. AMAG...
BioCentury | Jun 13, 2020
Finance

With nearly $1B raised overnight, quartet of offerings underscore demand for biotech IPOs

...a valuation of $91.7 million. Wednesday also saw a new addition to the IPO queue. Simcere Pharmaceutical Group Ltd....
...CROs and CMOs. Elizabeth S. Eaton, Staff Writer Avidity Biosciences Inc. Generation Bio Co. Lantern Pharma Inc. Burning Rock Biotech Ltd. Simcere Pharmaceutical Group Ltd. Vaxcyte...
BioCentury | Jun 12, 2020
Finance

June 11 Quick Takes: Biotech swept up in sell-off; plus Simcere, Lantern, Cue Health, C2i, BaseLaunch, Sanofi-Cathay and 4BIO

...and the S&P Biotech ETF (XBI) fell 6%. Simcere lines up for Hong Kong IPO Simcere Pharmaceutical Group Ltd....
...company’s oncology, neurology and autoimmune pipeline includes 50 candidates ranging from preclinical to late-stage development. Simcere...
...undisclosed investment in the firm’s second therapeutics-focused fund. BioCentury Staff Lantern Pharma Inc. Cue Health Inc. Pureos Bioventures Sanofi Cathay Capital 4BIO Capital Simcere Pharmaceutical Group Ltd. IPO...
BioCentury | Nov 16, 2019
Product Development

Major multinationals open, close, open R&D centers in China

...an R&D center in Beijing in 2011 and formed a JV the same year with Simcere...
Items per page:
1 - 10 of 119
BioCentury | Feb 5, 2021
Emerging Company Profile

Deals with Allogene, ADC reflect Overland’s ambition to tap parent Hillhouse’s network to bring innovation to China

...Euronext:SAN; NASDAQ:SNY). Mu is a veteran of Simcere Pharmaceutical Group Ltd....
...president of R&D and later president of Simcere’s...
BioCentury | Dec 31, 2020
Regulation

119 drugs added to China’s reimbursement list, which includes more domestic PD-1s

...Commission.Over 85% of NHSA’s disease categories were covered by added drugs, including Sanbexin edaravone/dexborneol from Simcere Pharmaceutical Group Ltd....
BioCentury | Dec 22, 2020
Regulation

Dec. 21-23 Regulatory Quick Takes: positive CHMP opinion for Pfizer-BioNTech COVID-19 vaccine; plus Urovant’s approval, a Feb. 9 adcomm for Keytruda in TNBC, NMPA reviewing a subcutaneous PD-L1, and more

...from urge urinary incontinence, urgency and urinary frequency.NMPA reviewing subcutaneous PD-L1 inhibitorAlphamab Oncology Ltd. and Simcere Pharmaceutical Group Ltd....
...deficient (dMMR) solid tumors. If approved, envafolimab could become the first subcutaneous anti-PD-1/PD-L1 antibody globally. Simcere...
BioCentury | Dec 15, 2020
Deals

Hillhouse’s Overland builds momentum with second marquee China deal with Allogene

...as a drug developer includes tenures at Simcere Pharmaceutical Group Ltd....
...president of R&D and later president of Simcere’s...
BioCentury | Dec 15, 2020
Deals

ADC Therapeutics caps year of milestones by building bridge to China via Hillhouse-backed Overland’s debut deal

...CMO Hua Mu, is a veteran of Simcere Pharmaceutical Group Ltd....
...president of R&D and later president of Simcere’s...
BioCentury | Oct 28, 2020
Finance

Oct. 27 Financial Quick Takes: Apellis-Sobi deal for C3 inhibitor; plus Primmune, Prokarium, Novartis-RegenxBio, Turning Point, Psyomics, Journey Colab

...reimbursements. It’s also eligible for $915 million in milestones.Simcere slips in Hong Kong debutShares of Simcere Pharmaceutical Group Ltd....
...The deal came at a valuation of about $4.6 billion. Once primarily a generics company, Simcere...
BioCentury | Oct 15, 2020
Product Development

Oct. 14 Quick Takes: FDA approves first Ebola therapy; plus Vertex tumbles after hours on AAT discontinuation

...Ventures and Octopus Ventures. Existing investors Amadeus Capital Partners, Delin Ventures and Kindred Capital also participated.Simcere...
...the midpoint, the company would raise HK$3.4 billion (US$433.7 million) and be valued HK$33.6 billion. Simcere...
...SGI-110, s110) Makena (gestiva, hydroxyprogesterone caproate injection, 17P) Regeneron Pharmaceuticals Inc. Vertex Pharmaceuticals Inc. Otsuka Pharmaceutical Factory Inc. Ori Biotech Ltd. Simcere Pharmaceutical Group Ltd. AMAG...
BioCentury | Jun 13, 2020
Finance

With nearly $1B raised overnight, quartet of offerings underscore demand for biotech IPOs

...a valuation of $91.7 million. Wednesday also saw a new addition to the IPO queue. Simcere Pharmaceutical Group Ltd....
...CROs and CMOs. Elizabeth S. Eaton, Staff Writer Avidity Biosciences Inc. Generation Bio Co. Lantern Pharma Inc. Burning Rock Biotech Ltd. Simcere Pharmaceutical Group Ltd. Vaxcyte...
BioCentury | Jun 12, 2020
Finance

June 11 Quick Takes: Biotech swept up in sell-off; plus Simcere, Lantern, Cue Health, C2i, BaseLaunch, Sanofi-Cathay and 4BIO

...and the S&P Biotech ETF (XBI) fell 6%. Simcere lines up for Hong Kong IPO Simcere Pharmaceutical Group Ltd....
...company’s oncology, neurology and autoimmune pipeline includes 50 candidates ranging from preclinical to late-stage development. Simcere...
...undisclosed investment in the firm’s second therapeutics-focused fund. BioCentury Staff Lantern Pharma Inc. Cue Health Inc. Pureos Bioventures Sanofi Cathay Capital 4BIO Capital Simcere Pharmaceutical Group Ltd. IPO...
BioCentury | Nov 16, 2019
Product Development

Major multinationals open, close, open R&D centers in China

...an R&D center in Beijing in 2011 and formed a JV the same year with Simcere...
Items per page:
1 - 10 of 119